Bioglutide (also known as NA-931) is an experimental oral quadruple receptor agonist designed for the treatment of obesity and metabolic disorders. Developed by Biomed Industries, it is categorized as a novel metabolic regulator that activates four key receptors: GLP-1, GIP, IGF-1, and Glucagon.